Emerging treatment options for patients with Laron syndrome

Bibliography

• Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone. A new inborn error of metabolism? Isr J Med Sci 1966;2:153-5
   Google Scholar
• Laron Z, Pertzelan A, Karp M. Pituitary dwarfism with high serum levels of growth hormone. Isr J Med Sci 1968;4:883-94
   PubMedGoogle Scholar
• Laron Z. Laron type dwarfism (hereditary somatomedin deficiency): a review. In: Frick P, Von Harnack GA, Kochsiek GA, Prader A, editors. Adv Int Med Pediat. Springer-Verlag, Berlin-Heidelberg; 1984. p. 51:117-50
   Google Scholar
• Laron Z. Laron syndrome (primary growth hormone resistance on insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab 2004;89:1031-44
   PubMed Web of Science ®Google Scholar
• Laron Z, Kopchick JJ. editors. Laron syndrome-from man to mouse. Springer-Verlag, Heidelberg, New York; 2011. p. 531
   Google Scholar
• Keret R, Pertzelan A, Zeharia A, et al. Growth hormone (hGH) secretion and turnover in three patients with Laron-type dwarfism. Isr J Med Sci 1988;34:75-9
   Google Scholar
• Laron Z, Efros O. Lifelong serum growth hormone levels in patients with Laron syndrome. In: Laron Z, Kopchick JJ, editors. Laron syndrome from man to mouse. Springer-Verlag; Heidelberg, New York; 2011. p. 235-9
   Google Scholar
• Daughaday WH, Laron Z, Pertzelan A, et al. Defective sulfation factor generation: a possible etiological link in dwarfism. Trans Assoc Am Physicians 1969;82:129-38
   PubMedGoogle Scholar
• Laron Z, Pertzelan A, Karp M, et al. Administration of growth hormone to patients with familial dwarfism with high plasma immunoreactive growth hormone. Measurement of sulfation factor, metabolic and linear growth responses. J Clin Endocrinol Metab 1971;33:332-42
   PubMedGoogle Scholar
• Laron Z. Diagnosis of Laron syndrome. In: Laron Z, Kopchick JJ, editors. Laron syndrome-from man to mouse. Springer-Verlag; Heidelberg, New York; 2011. p. 27-8
   Google Scholar
• Eshet R, Laron Z, Brown M, et al. Immunoreactive properties of the plasma hGH from patients with the syndrome of familial dwarfism and high plasma IR-hGH. J Clin Endocrinol Metab 1973;37:819-21
   PubMedGoogle Scholar
• Eshet R, Laron Z, Brown M, et al. Immunological behavior of hGH from plasma of patients with familial dwarfism and high IR-hGH in a radioimmunoassay system using the cross-reaction between hGH and HCS. Horm Metab Res 1974;6:80-1
   PubMedGoogle Scholar
• Russell RE, Parks JS, McKean MC, et al. Laron-type dwarfism is associated with normal growth hormone and insulin-like growth factor I gene restriction patterns. Isr J Med Sci 1989;25:342-4
   PubMedGoogle Scholar
• Laron Z, Kowadlo-Silbergeld A, Eshet R. Growth Hormone Resistance. Ann Clin Res 1980;12:269-77
   PubMedGoogle Scholar
• Eshet R, Laron Z, Pertzelan A, et al. Defect of human growth hormone in the liver of two patients with Laron type dwarfism. Isr J Med Sci 1984;20:8-11
   PubMedGoogle Scholar
• Geffner ME, Golde DW, Lippe BM, et al. Tissues of the Laron dwarf are sensitive to insulin-like growth factor I but not to growth hormone. J Clin Endocrinol Metab 1987;64:1042-6
   PubMedGoogle Scholar
• Godowski PJ, Leung DW, Meacham LR, et al. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron type dwarfism. Proc Natl Acad Sci USA 1989;86:8083-7
   PubMed Web of Science ®Google Scholar
• Amselem S, Duquesnoy P, Attree O, et al. Laron dwarfism and mutations of the growth hormone-receptor gene. N Engl J Med 1989;321:989-95
   PubMed Web of Science ®Google Scholar
• Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J. Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 1994;15:369-90
   PubMedGoogle Scholar
• Rosenbloom AL, Guevara-Aguirre J. Growth hormone receptor deficiency in South America: colonial history, molecular biology, and growth and metabolic insights. J Pediatr Endocrinol Metab 2008;21:1107-19
   PubMedGoogle Scholar
• Savage MO, Attie KM, David A, et al. Endocrine, molecular characterization and treatment of growth hormone insensitivity disorders. Nat Clin Pract Edocrinol Metab 2006;2:395-407
   PubMedGoogle Scholar
• Shevah O, Laron Z. Genetic analysis of the pedigrees and molecular defects of the GH-receptor gene in the Israeli cohort of patients with Laron syndrome. Pediatr Endocrinol Rev 2006;3(Suppl 3):489-97. Erratum in: Pediatr Endocrinol Rev. 2007;5:470
   PubMedGoogle Scholar
• Shevah O, Laron Z. Genetic aspects. In: Laron Z, Kopchick JJ, editors. Laron syndrome-from man to mouse. Springer; Heidelberg, New York; 2011. p. 29-48
   Google Scholar
• David A, Hwa V, Metherell LA, et al. Evidence for a continuum of genetic, phenotypic, and biochemical abnormalities in children with growth hormone insensitivity. Endocr Rev 2011;32:472-97
   PubMed Web of Science ®Google Scholar
• Niwa M, Sato Y, Uchiyama F, et al. Chemical synthesis, cloning and expression of genes for human somatomedin C (insulin like growth factor I) and 5aval somatomedin C. Ann NY Acad Sci 1986;469:31-52
   PubMedGoogle Scholar
• Rinderknecht E, Humbel RE. The amino acid sequence of human insulin like growth factor I and its structural homology with proinsulin. J Biol Chem 1978;253:2769-76
   PubMed Web of Science ®Google Scholar
• Blundell TL, Humbel RE. Hormone families: pancreatic hormones and homologous growth factors. Nature 1980;287:781-7
   PubMed Web of Science ®Google Scholar
• Laron Z. Somatomedin-I (recombinant insulin-like growth factor-I). Clinical pharmacology and potential treatment of endocrine and metabolic disorders. BioDrugs 1999;11:55-70
   PubMedGoogle Scholar
• Jones JI, Clemmos DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34
   PubMed Web of Science ®Google Scholar
• Bach LA, Rechler MM. Insulin-like growth factor binding proteins. Diabetes Rev 1995;3:38-61
   Google Scholar
• Zapl J. Physiological role of the insulin-like growth factor binding proteins. Euro J Endocrinol 1995;132:645-54
   PubMedGoogle Scholar
• McCusker RH, Clemmons DR. The insulin-like growth factor binding proteins: structure and biological functions. In: Schofield PN, editor. The insulin-like growth factors: structure and biological functions. Oxford University Press, New York; 1992. p. 110-50
   Google Scholar
• Baxter RC. Circulating binding proteins for the insulin-like growth factors. Trends Endocrinol Metab 1993;4:91-6
   PubMedGoogle Scholar
• Silbergeld A, Litwin A, Bruchis S, et al. Insulin-like growth factor (IGF-I) in healthy children, adolescents and adults as determined by a radioimmunoassay specific for the synthetic 53-70 peptide region. Clin Endocrinol (Oxf) 1986;25:67-74
   PubMedGoogle Scholar
• Guler HP, Zapf J, Schmid C, et al. Insulin-like growth factors I and II in healthy man. Estimations of half lives and production rates. Acta Endocrinol 1989;121:753-8
   PubMedGoogle Scholar
• Laron Z, Pertzelan A, Doron M, et al. The effect of dihydrosomatostatin in dwarfism with high plasma immunoreactive growth hormone. Horm Metab Res 1977;9:338-9
   PubMedGoogle Scholar
• Klinger B, Garty M, Laron Z. Elimination characteristics of intravenously administered rIGF-I in Laron-type dwarfs. Dev Pharmacol Ther 1990;15:196-9
   PubMedGoogle Scholar
• Laron Z, Klinger B, Blum WF, et al. IGF binding protein 3 in patients with LTD: effect of exogenous rIGF-I. Clin Endocrinol (Oxf) 1992;36:301-4
   PubMedGoogle Scholar
• Grahnen A, Kastrup K, Heinrich U, et al. Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with hormone receptor deficiency. Acta Paediatr 1993;391(Suppl):7-13
   Google Scholar
• Laron Z, Klinger B, Erster B, et al. Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfism. Lancet 1988;2:1170-2
   PubMed Web of Science ®Google Scholar
• Laron Z, Klinger B, Silbergeld A, et al. Intravenous administration of recombinant IGF-I lowers serum GHRH and TSH. Acta Endocrinol (Copenh) 1990;123:378-82
   PubMedGoogle Scholar
• Walker JL, Ginalska-Malinowska M, Romer TE, et al. Effects of the infusion of insulin like growth factor I in a child with growth hormone insensitivity syndrome (Laron Dwarfism). N Engl J Med 1991;324:1483-8
   PubMed Web of Science ®Google Scholar
• Laron Z, Klinger B, Jensen LT, et al. Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism. Clin Endocrinol (Oxf) 1991;35:145-50
   PubMed Web of Science ®Google Scholar
• Silbergeld A, Klinger B, Schwartz H, et al. Serum prolactin in patients with Laron type dwarfism: effect on insulin like growth factor 1. Horm Res 1992;37:160-4
   PubMedGoogle Scholar
• Laron Z, Klinger B. Effect of insulin-like growth factor-I treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance). Eur J Endocrinol 1998;138:176-80
   PubMedGoogle Scholar
• Gafny M, Silbergeld A, Klinger B, et al. Comparative effects of GH, IGF-I and insulin on sex hormone binding globulin. Clin Endocrinol (Oxf) 1994;41:169-75
   PubMedGoogle Scholar
• Vaccarello MA, Diamond FB, Guevara-Aguirre J Jr, et al. Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. J Clin Endocrinol Metab 1993;77(1):273-80
   PubMedGoogle Scholar
• Kanety H, Karasik A, Klinger B, et al. Long-term treatment of Laron type dwarfs with insulin-like growth factor I increases serum insulin-like growth factor-binding protein 3 in the absence of growth hormone activity. Acta Endocrinol 1993;128:144-9
   PubMedGoogle Scholar
• Kanety H, Silbergeld A, Klinger B, et al. Long-term effects of insulin-like growth factor-I (IGF-I) on serum IGF-I, IGF binding protein 3 (IGFBP3) and acid labile subunit in Laron syndrome patients with normal GHBP. Eur J Endocrinol 1997;137:626-30
   PubMed Web of Science ®Google Scholar
• Laron Z, Klinger B, Blum WF, et al. IGF binding protein 3 in patients with LTD: effect of exogenous rIGF-I. Clin Endocrinol (Oxf) 1992;36:301-4
   PubMedGoogle Scholar
• Laron Z, Anin S, Klipper-Aurbach Y, et al. Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet 1992;339:1258-62
   PubMed Web of Science ®Google Scholar
• Walker JL, Van Wyk JJ, Underwood LE. Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron type). J Pediatr 1992;10:641-6
   Google Scholar
• Wilton P; on behalf of the Kabi Pharmacia Study Group on Insulin-Like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes. Treatment with recombinant human insulin-like growth factor I of children with growth hormone receptor deficiency (Laron syndrome). Acta Paediatr Suppl 1992;383:137-41
   PubMedGoogle Scholar
• Laron Z. One-year treatment with IGF-I of children with Laron syndrome. Clin Courier 1993;11:7-8
   Google Scholar
• Heinrichs C, Vis HL, Bergmann P, et al. Effects of 17 months treatment using recombinant insulin-like growth factor-I in two children with growth hormone insensitivity (Laron) syndrome. Clin Endocrinol (Oxf) 1993;38:647-51
   PubMedGoogle Scholar
• Martinez V, Vasconez O, Martinez AL, et al. Body changes in adolescent patients with growth hormone receptor deficiency receiving recombinant human insulin-like growth factor I and luteinizing hormone-releasing hormone analogue: preliminary results. Acta Paediatr Suppl 1994;399:133-6
   PubMedGoogle Scholar
• Ranke MB, Savage MO, Chatelain PG, et al. Insulin-like growth factor I improves height in growth hormone insensitivity: two years' results. Horm Res 1995;44:253-64
   PubMed Web of Science ®Google Scholar
• Guevara-Aguirre J, Rosenbloom AL, Vasconez O, et al. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH deficiency. J Clin Endocrin Metab 1997;82(2):629-33
   PubMedGoogle Scholar
• Azcona C, Preece MA, Rose J, et al. Growth response to rhIGF-I 80 μg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype. Clin Endocrin (Oxf) 1999;51:787-92
   PubMed Web of Science ®Google Scholar
• Walker JL, Crock PA, Behnchken SN, et al. A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to long-term treatment with recombinant human insulin-like growth factor-I and luteinizing hormone-releasing hormone analogue. J Clin Endocrinol Metab 1998;83:2554-61
   PubMedGoogle Scholar
• Besson A, Salemi S, Eblé A, et al. Primary GH insensitivity (Laron syndrome) caused by a novel 4kb deletion encompassing exon 5 of the GH receptor gene: effect of intermittent long-term treatment with recombinant human IGF-I. Europ J Endocrinol 2004;150:635-42
   PubMedGoogle Scholar
• Kržiŝnik V, Battelino T. Five year treatment with IGF-I of a patient with Laron syndrome in Slovenia. J Pediat Endocrinol Metab 1997;10:443-7
   PubMedGoogle Scholar
• Zucchini S, Scarano E, Baldazzi L, et al. Final height in a patient with Laron syndrome after long-term therapy with rhIGF-I and short-term therapy with LHRG-analogue and oxandrolone during puberty. J Endocrinol Invest 2005;28:274-9
   PubMedGoogle Scholar
• Kaji H, Nose O, Tajiri H, et al. Novel compound heterozygous mutation of growth hormone (GH) receptor gene in a patient with GH insensitivity syndrome. J Clin Endocrinol Metab 1997;82:3705-9
   PubMedGoogle Scholar
• Ranke MB, Savage MO, Chatelain PG, et al. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. Horm Res 1999;51:128-34
   PubMed Web of Science ®Google Scholar
• Backeljaw P F, Underwood LE; and the GHIS Collaborative Group. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome – a clinical research center study. J Clin Endocrinol Metab 1996;81:3312-17
   PubMedGoogle Scholar
• Backeljaw PF, Underwood LE; and the GHIS Collaborative Group. Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metab 2001;86:1504-10
   PubMedGoogle Scholar
• Chernausek SD, Backeljauw PF, Frane J, et al. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007;92:902-10
   PubMed Web of Science ®Google Scholar
• Backeljaw PF, Chernausek SD. The insulin-like growth factors and growth disorders of childhood. Endocrinol Metab Clin North Am 2012;41:265-82
   PubMedGoogle Scholar
• Backeljaw Ph F, Kuntze J, Frane J, et al. Adult and near-adult height in patients with severe insulin-like growth factor-I deficiency after long-term therapy with recombinant human insulin-like growth factor-I. Horm Res Paediatr 2013;80:47-56
   PubMedGoogle Scholar
• Underwood L, Chernausek SD, Kuntze J, et al. Efficacy of Long-term treatment with recombinant human IGF-I (rhlGF-I) of children with GH insensitivity [abstract P3-451]. 86th Annual Meeting of the Endocrine Society; New Orleans, LA, USA; 2004. 575
   Google Scholar
• Frane J, Bailly J, Chernausek S, et al. Growth responses to higher dose recombinant human IGF-I (rhIGF-I) in children with severe primary IGF-I deficiency (IGFD) due to growth hormone insensitivity (GHIS) [abstract P03-619]. Horm Res 2006;65(Suppl 4):180
   Google Scholar
• Klinger B, Laron Z. Three year IGF-I treatment of children with Laron syndrome. J Clin Endocrinol Metab 1995;8:149-58
   Google Scholar
• Laron Z. Insulin-like growth factor-I treatment of children with laron syndrome (primary growth hormone insensitivity). Pediatr Endocrinol Rev 2008;5(3):766-71
   PubMedGoogle Scholar
• Laron Z. IGF-I treatment of patients with Laron syndrome. In: Laron Z, Kopchick JJ, editors. Laron syndrome from man to mouse. Springer, Heidlberg, New York; 2011. p. 343-80
   Google Scholar
• Laron Z, Ginsberg S, Lilos P, et al. Long-term IGF-I treatment of children with Laron syndrome increases adiposity. Growth Horm IGF Res 2006;16:61-4
   PubMed Web of Science ®Google Scholar
• Laron Z. Effects of long-term administration of IGF-I on the adipose tissue and carbohydrate metabolism in children with Laron syndrome. In: Laron Z, Kopchick JJ, editors. Laron syndrome from man to mouse. Springer, Heidlberg, New York; 2011. p. 389-408
   Google Scholar
• Laron Z, Silbergeld A, Kauli R. Differential effects of hGH and IGF-I on body proportions. Anthropol Anz (J Biol Clinic Anthrop) 2012;69:255-9
   PubMedGoogle Scholar
• Laron Z. If one daily injection of IGF-I has the same growth promoting effect as 2 injections a day why continue to give two injections? Pediatr. Encocrinol Rev 2013;10:277-9
   PubMedGoogle Scholar
• Ranke MB. Clinical considerations in using growth hormone therapy in growth hormone deficiency. In: Hindmarsh PC, editor. Current indications for growth hormone therapy. Revised 2nd edition. Endocr Dev Basel, Karger; Basel; 2010. p. 18:83-91
   Google Scholar
• Green H, Morikawa M, Nixton T. A dual effector theory of growth hormone action. Differentiation 1985;29:195-8
   PubMed Web of Science ®Google Scholar
• Liu J-L, LeRoith D. Insulin-like growth factor I is essential for postnatal growth in response to growth hormone. Endocrinology 1999;140:5178-84
   PubMed Web of Science ®Google Scholar
• Laron Z, Iluz M, Kauli R. Head circumference in untreated and IGF-I treated patients with Laron syndrome Comparison with untreated and hGH-treated children with isolated growth hormone deficiency. Growth Horm IGF Res 2012;22:49-52
   PubMedGoogle Scholar
• Konen O, Silbergeld A, Lilos P, et al. Hand size and growth in untreated and IGF-I treated patients with Laron syndrome. Pediatr Nephrol 1994;8:684-8
   PubMedGoogle Scholar
• Silbergeld A, Lilos P, Laron Z. Foot length before and during insulin-like growth factor-I treatment of children with Laron syndrome compared to human growth hormone treatment of children with isolated growth hormone deficiency. J Pediatr Endocrinol Metab 2007;20:1325-8
   PubMedGoogle Scholar
• Klinger B, Laron Z. Renal function in Laron syndrome patients treated by insulin-like growth factor-I. Pediatr Nephrol 1994;8:684-8
   PubMedGoogle Scholar
• Sivan B, Lilos P, Laron Z. Effects of insulin-like growth factor-I deficiency and replacement therapy on the hematopoietic system in patients with Laron syndrome (primary growth hormone insensitivity). J Pediatr Endocrinol Metab 2003;16:509-20
   PubMedGoogle Scholar
• Attias J, Zarchi O, Nageris BI, et al. Cochlear hearing loss in patients with Laron syndrome. Eur Arch Otorhinolaryngol 2012;269:461-6
   PubMed Web of Science ®Google Scholar
• Laron Z, Wang XL, Klinger B, et al. Insulin-like growth factor-I decreases serum lipoprotein (a) during long-term treatment of patients with Laron syndrome. Metabolism 1996;45(10):1263-6
   PubMedGoogle Scholar
• Laron Z, Klinger B. IGF-I treatment of adult patients with Laron syndrome: preliminary results. Clin Endocrinol (Oxf) 1994;41(5):631-8
   PubMed Web of Science ®Google Scholar
• Klinger B, Jensen LT, Silbergeld A, et al. Insulin-like growth faction –I raises serum procollagen levels in children and adults with Laron syndrome. Clin Endocrinol (Oxf) 1996;45:423-9
   PubMedGoogle Scholar
• Ben-Amitai D, Laron Z. Effect of insulin-like growth factor-I deficiency or administration on the occurrence of microcomedones and acne. J Eur Acad Dermatol Venereol 2011;25:950-4
   PubMed Web of Science ®Google Scholar
• Mauras N, Martinez V, Rini A, et al. Recombinant human insulin-like growth factor I have significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism. J Clin Endocrinol Metab 2000;85(1):3036-42
   PubMedGoogle Scholar
• Feinberg MS, Scheinowitz M, Laron Z. Echocardiographic dimensions and function in adults with primary growth hormone resistance (Laron syndrome). Am J Cardiol 2000;85:209-13
   PubMedGoogle Scholar
• Norman P. SomatoKine, Insmed. Curr Opin Investig Drugs 2003;4:466-71
   PubMedGoogle Scholar
• Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002;23:824-54
   PubMed Web of Science ®Google Scholar
• Camacho-Hübner C, Storr HI, Miraki-Moud F, et al. Pharmacokinetic studies of rhIGF-I/rhIGFBP-3 complex administered to patients with growth hormone insensitivity syndrome (GHIS) [abstract P2-356]. 85th Annual Meeting of the Endocrine Society, Chevy Chase, Md. The Endocrine Society; June 2003; Philadelphia, Pennsylvania; 2003
   Google Scholar
• Barr WH, Garnett WR, Chinchilli VM, et al. Pharmacokinets of single dose subcutaneous administration of rhIGF-I/rhIGFBP-3 in healthy adult volunteers [abstract #P1-191]. Endocr Soc 88th Ann Meeting; Boston Mass. 2006. 209
   Google Scholar
• Camacho-Hübner C, Rose S, Preece MA, et al. Pharmacokinetic studies of recombinant human insulin-like growth factor I rhIGF-I/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome. J Clin Endocrnol Metab 2006;91:1246-52
   PubMed Web of Science ®Google Scholar
• Savage M, Underwood L, Yordam N, et al. Treatment of short stature in children with severe primary IGF-I deficiency with once daily rhIGF-I/rhIGFBP-3 administration [abstract # CF1-100]. Europ Soc Paed Soc, 45th Ann Meeting Rotterdam. Horm Res 2006;65(Suppl 4):30
   Google Scholar
• Tonella P, Flück CE, Mullis PE. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex. Horm Res Paediatr 2010;73:140-7
   PubMed Web of Science ®Google Scholar
• Besson A, Salemi S, Eble A, et al. Primary GH insensitivity (Laron's syndrome) caused by a novel 4kb deletion encompassing exon 5 of the GH receptor gene: effect of intermittent long-term treatment with recombinant human IGF-I. Eur J Endocrinol 2004;150:635-42
   PubMedGoogle Scholar
• Ekström K, Carlsson-Skwirut C, Ritzén EM, et al. Insulin-Like growth factor-I and insulin-like growth factor binding protein-3 cotreatment versus insulin-like growth factor-1 alone in two brothers with growth hormone insensitivity syndrome: effects on insulin sensitivity, body composition and linear growth. Horm Res Paediatr 2011;76:355-66
   PubMed Web of Science ®Google Scholar
• Enberg B, Luthman H, Segnestam K, et al. Characterisation of novel missense mutations in the GH receptor gene causing severe growth retardation. Eur J Endocrinol 2000;143:71-6
   PubMedGoogle Scholar
• Saukkonen T, Amin R, Williams RM, et al. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes. J Clin Endocrinol Metab 2004;89:4634-41
   PubMed Web of Science ®Google Scholar
• Williams RM, McDonald A, O'Savage M, et al. Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEXTM. Expert Opin Metab Toxicol 2008;4:311-24
   PubMed Web of Science ®Google Scholar
• EI Kholy M, Elsedfy HH. Effect of GnRH analogue on height potential in patients with severe growth hormone insensitivity syndrome treated with IGF-I. J Pediatr Endocrinol Metab 2011;24:983-98
   PubMedGoogle Scholar
• Guevara-Aguirre J, Rosenbloom AL, Guevara-Aguirre M, et al. Recommended IGF-I dosage causes greater fat accumulation and osseous maturation than lower dosage and may compromise long-term growth effects. J Clin Endocrinol Metab 2013;98(2):839-45
   PubMed Web of Science ®Google Scholar
• Laron Z, Ginsberg S, Webb M. Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion – preliminary report. Growth Horm IGF Res 2008;18:434-8
   PubMedGoogle Scholar
• Bisker-Kassif O, Kauli R, Lilos P. Biphasic response of subscapular skinfold thickness to hGH or IGF-1 administration to patients with congenital IGHD, congenital MPHD and Laron syndrome. Obes Res Clin Pract 2012, doi.org/10.106/j.orcp. 2012.11.001
   Google Scholar
• Ginsberg S, Laron Z, Arbiv Bed M, et al. The obesity of patients with Laron syndrome is not associated with excessive nutritional intake. Obesity Res Clin Pract 2009;3:3-8
   Google Scholar
• Kornreich L, Horev G, Schwarz M, et al. Craniofacial and brain abnormalities in Laron syndrome (primary growth hormone insensitivity). Eur J Endocrinol 2002;146:499-503
   PubMedGoogle Scholar
• Dagan Y, Abadi J, Lifschitz A, et al. Severe obstructive sleep apnoea syndrome in an adult patient with Laron syndrome. Growth Horm IGF Res 2001;11:247-9
   PubMedGoogle Scholar
• Laron Z, Silbergeld A, Klinger B. Hyperandrogenism induced by insulin-like growth factor-I (IGF-I) treatment of two girls with Laron Syndrome. Hosp Q 1998;10:75-9
   Google Scholar
• Klinger B, Anin S, Silbergeld A, et al. Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron syndrome. Clin Endocrinol (Oxf) 1998;48:81-7
   PubMedGoogle Scholar
• Galatzer A, Aran O, Nagelberg N, et al. Cognitive and psychosocial functioning of young adults with Laron syndrome. In: Laron Z, Parks JS, editors. Lessons from Laron syndrome (LS) 1966-1992. Pediatric and adolescent endocrinology, Karger, Basel New York; 1993. p. 24:53-60
   Google Scholar
• Laron Z, Avitzur Y, Klinger B. Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor-I treatment. Metabolism 1995;44(4):113-18
   PubMedGoogle Scholar
• Agladioglu SY, Cetinkaya S, Erdeve SS, et al. Diabetes mellitus with Laron syndrome: case report. J Pediatr Endocrinol Metab 2013;26(9-10):955-8
   PubMedGoogle Scholar
• Laron Z, Weinberger D. Diabetic retinopathy in two patients with congenital IGF-I deficiency (Laron syndrome). Eur J Endocrinol 2004;151:103-6
   PubMed Web of Science ®Google Scholar
• Laron Z, Kauli R, Rosenzweig E. Sleep and sleep disorders in patients with Laron syndrome. In: Laron Z, Kopchick JJ, editors. Laron syndrome-from man to mouse. Springer, Heidelberg, New York; 2011. p. 317-20
   Google Scholar
• Ben-Dov I, Gaides M, Scheinowitz M, et al. Reduced exercise capacity in untreated adults with primary growth hormone resistance (Laron syndrome). Clin Endocrinol (Oxf) 2003;59:763-7
   PubMedGoogle Scholar
• Laron Z, Kauli R. Orthopedic problems in Laron syndrome. In: Laron Z, Kopchick JJ, editors. Laron syndrome-from man to mouse. Springer, Heidelberg, New York; 2011. p. 323-33
   Google Scholar
• Kornreich L, Horev G, Schwarz M, et al. Laron syndrome abnormalities: Spinal stenosis, os odontoideum, degenerative changes of the atlanto-odontoid joint, and a small oropharynx. Am J Neuroradiol 2002;23:625-31
   PubMedGoogle Scholar
• Hellstrom A, Carlsson B, Niklasson A, et al. IGF-I is critical for normal vascularization of the human retina. J Clin Endocrinol Metab 2002;87:3413-16
   PubMed Web of Science ®Google Scholar
• Bourla D, Laron Z, Snir M, et al. Insulin-like growth factor I affects ocular development: a study of untreated and treated patients with Laron syndrome. Ophtalmology 2006;113:1197-200
   PubMed Web of Science ®Google Scholar
• Zhao X, Donovan M. Combined growth hormone (GH) and insulin-like growth factor-I (IGF-I) treatment is more effective than GH or IGF-I alone at enhancing recovery from neonatal malnutrition in rats. J Nutr 1995;125:2773-86
   PubMed Web of Science ®Google Scholar
• Barner C, Petersson M, Engström BE, et al. Effects on insulin sensitivity and body composition of combination therapy with GH and IGF-I in GH deficient adults with type 2 diabetes. Europ J Endocrinol 2012;167:697-703
   PubMed Web of Science ®Google Scholar
• Holloway L, Butterfield G, Hintz RL, et al. Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. J Clin Endocrinol Metab 1994;79:470-9
   PubMedGoogle Scholar
• Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1587-609
   PubMed Web of Science ®Google Scholar
• Sondergaard E, Klose M, Hansen M, et al. Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency. J Clin Endocrinol Metab 2011;96(3):681-8
   PubMedGoogle Scholar
• Luca G, Calvitti M, Mancuso F, et al. Reversal of experimental Laron syndrome by xenotransplantation of microencapsulated porcine Sertoli cells. J Control Release 2013;165:75-81
   PubMedGoogle Scholar
• Laron Z, Klinger B. Are patients with Laron syndrome candidates for limb lengthening? In: Laron Z, Mastragastino S, Romano C, editors. Limb lengthening for whom, when and how. Freund Publ House, London; 1995. p. 79-91
   Google Scholar
• Benbassat CA, Eshed V, Kamjin M, et al. Are adult patients with Laron syndrome osteopenic? A comparison between dual-energy X-ray absorptiometry and volumetric bone densities. J Clin Endocrinol Metab 2003;88(10):4586-9
   PubMedGoogle Scholar
• Shevah O, Laron Z. Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Horm IGF Res 2007;17:54-7
   PubMed Web of Science ®Google Scholar
• Steuerman R, Shevah O, Laron Z. Congenital IGF-I deficiency tends to confer protection against post-natal development of malignancies. Euro J Endocr 2011;164:485-9
   PubMed Web of Science ®Google Scholar
• Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer and diabetes in humans. Sci Transl Med 2011;3(70):70ra13
   PubMed Web of Science ®Google Scholar